3309 (3309) Fair Value & Analysis

Healthcare · Market cap HK$1.2B

3 3309 3309 · HK

PriceHK$0.9600

Fair ValueHK$1.82

Upside+89.6%

Quality59/100

Watch 3309 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$1.37 – HK$2.28

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −7.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.9400 – HK$2.09 · fair‑value band HK$1.37 – HK$2.28 · the HK$0.9600 price screens below the HK$1.82 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3309 (3309) currently trades at HK$0.9600, while our model-based Fair Value estimate is HK$1.82 — implying the stock looks roughly 89.6% undervalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 3309 generated revenue of HK$1.9B at a net margin of 5.2%. Revenue grew 1.2% year over year. It earns a return on equity of 5.8%. Net debt stands at HK$78.9M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.9B

Revenue growth (YoY) +1.2%

Net margin 5.2%

Return on equity 5.8%

Free cash flow HK$224M FY2025

P/E ratio 11.9

More key figures

Operating margin 7.6%

EPS (TTM) HK$0.0400

Dividend yield 2.1%

EPS growth (YoY) +65.7%

Net debt HK$78.9M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3309 reported revenue of HK$1.9B in FY2025 versus HK$1.1B in FY2021, a compound +15.0%/yr. Reported net income was HK$100M in FY2025, compounding +46.4%/yr from FY2021.

Revenue +15.0%/yr

FY21 HK$1.1B

FY22 HK$1.7B

FY23 HK$1.9B

FY24 HK$1.9B

FY25 HK$1.9B

Net income +46.4%/yr

FY21 HK$21.9M

FY22 −HK$21.9M

FY23 HK$62.0M

FY24 −HK$135M

FY25 HK$100M

Is 3309 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3309 (3309) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.82 versus a price of HK$0.9600 — about +90% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 3309?

Our model-based fair value for 3309 is HK$1.82 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.9600.

What is the quality score of 3309?

3309 has a Quality Score of 59/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3309 (3309)?

3309 reported trailing-twelve-month revenue of about HK$1.9B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3309?

The net profit margin of 3309 is about 5.2%, meaning it keeps roughly 5.2% of revenue as net income. Based on the latest reported figures.

Does 3309 pay a dividend?

3309 currently shows a dividend yield of about 2.13% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.